___

• Jeffery TK, Wanstall JC. Pulmonary vascular remodeling: A target for therapeutic intervention in pulmonary hypertension. Pharmacol Ther 2001;92:1-20.
• Khoury J, Langleben D. Heparin-like molecules inhibit pulmonary vascular pericyte proliferation in vitro. J Neurophysiology 2000;279:252-61.
• Perreault T, Berkenbosch JW, Barrington KJ, Decker ER, Wu C, Brock TA, et al. J. TBC3711, an ET(A) receptor antagonist, reduces neonatal hypoxia-induced pulmonary hypertension in piglets. Pediatr Res 2001;50:374-83.
• Rabinovitch M. Pathobiology of pulmonary hypertension. Clinics Chest Med 2001; 22:433-49.
• Yamashita Y, Nakagomi K, Takeda T, Hasegawa S, Mitsui Y. Effect of heparin on pulmonary fibroblasts and vascular cells. Thorax 1992;47:634-9.
• Fratacci MD, Frostell CG, Chen TY, Wain JC Jr, Robinson DR, Zapol WM. Inhaled nitric oxide. A selective pulmonary vasodilator of heparin-protamine vasoconstriction in sheep. Anesthesiology 1991;75:990-9.
• Dickey LA, Butler TJ, Bergmann TM, Bates ME, Null DM. Selective heparinization of the extracorporeal membrane oxygenation circuit using continuous infusions of protamine and heparin in short-term pig model. Perfusion 1994;9:327-33.